Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7386 p125
4 February 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Society presents evidence at inquiry into NHS charges in England

Rob Darracott

Rob Darracott: difficult issue

Abolition of NHS prescription charges in Wales next year could influence what happens to the system in England, the Royal Pharmaceutical Society predicted this week.

Rob Darracott, director of corporate and strategic development at the Society, said that what happens in Wales would provide some clues as to what might happen in England were that system to be followed.

His comments came ahead of the meeting of the House of Commons Health Committee on 2 February where he was due to give evidence to its inquiry into NHS charges, which includes prescription charges.

Mr Darracott welcomed the inquiry because reviewing charges, particularly prescription charges “has always been considered to be one of those things which is so difficult that nobody wants to go there. I also think it is interesting that the Health Committee has raised the subject in the first year of the new government. I think it has done that because the issue is so difficult.” The Society is one of 10 organisations, including the British Medical Association, the King’s Fund and patient charities, which were due to give evidence to the committee at its resumed inquiry this week.

The inquiry in England comes a year before prescription charges in Wales are due to be abolished following an earlier decision by the Welsh Assembly (PJ, 1 November 2003, p606).

Elsewhere in the UK, the Scottish Parliament has just launched an overhaul of exemptions of prescription charges, following the failure of a private member’s bill that would have meant Scotland following Wales’s lead and abolishing charges.

In Northern Ireland a spokeswoman for the department of health, social services and public safety confirmed it had no plans to change the current NHS charging system. She said: “We have been following the normal increases in prescription charges in line with the Department of Health in England. We have no plans to follow the Welsh proposal.”


News feature p128

Back to Top


©The Pharmaceutical Journal